ArticleCancer causes & control : CCC2009
C-reactive protein, interleukin-6, and prostate cancer risk in men aged 65 years and older.
Article in Cancer causes & control : CCC, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 3 syntheses or guidelines pooled it, 57 citations in OpenAlex.
- Statistical meta-analysis to investigate the association between the Interleukin-6 (IL-6) gene polymorphisms and cancer risk.PloS one · 2021Pooled it
- Meta-analysis of the role of IL-6 rs1800795 polymorphism in the susceptibility to prostate cancer: Evidence based on 17 studies.Medicine · 2017Pooled it
- Interleukin-6 gene -174G>C and -636G>C promoter polymorphisms and prostate cancer risk.Molecular biology reports · 2013Pooled it
- Association between prediagnostic biomarkers of inflammation and endothelial function and cancer risk: a nested case-control study.American journal of epidemiology · 2013Trial
- Genetic variation in RNASEL associated with prostate cancer risk and progression.Carcinogenesis · 2010Trial
- Article
- Relevance of Interleukins 6 and 8 Single Nucleotide Polymorphisms in Prostate Cancer: A Multicenter Study.Prostate cancer · 2021Article
- Genetically Predicted Circulating Level of C-Reactive Protein Is Not Associated With Prostate Cancer Risk.Frontiers in oncology · 2020Article
- Epidemiology of Prostate Cancer.World journal of oncology · 2019Review
- Serum biomarkers of inflammation for diagnosis of prostate cancer in patients with nonspecific elevations of serum prostate specific antigen levels.Translational cancer research · 2019Article
- The Role of Polymorphisms in Genes of PI3K/Akt Signaling Pathway on Prostate.Journal of Cancer · 2019Article
- Genetic polymorphisms of IL-6 promoter in cancer susceptibility and prognosis: a meta-analysis.Oncotarget · 2018Article
- The Pathologic Role of Toll-Like Receptor 4 in Prostate Cancer.Frontiers in immunology · 2018Review
- Association between interleukin-6 polymorphisms and urinary system cancer risk: evidence from a meta-analysis.OncoTargets and therapy · 2016Article
- Quantitative analysis of the association betweenOncology letters · 2015Article
- Association of Plasma Heat Shock Protein 70, Interleukin 6, and Creatine Kinase Concentrations in a Healthy, Young Adult Population.Journal of biomarkers · 2015Article
- Article
- Association of interleukin-6 (-174 G/C) polymorphism with the prostate cancer risk: A meta-analysis.Biomedical reports · 2014Article
- Genetic variation across C-reactive protein and risk of prostate cancer.The Prostate · 2014Article
- -174G/C polymorphism in the interleukin-6 promoter is differently associated with prostate cancer incidence depending on race.Genetics and molecular research : GMR · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
Abstract
Inflammation is believed to play a role in prostate cancer (PCa) etiology, but it is unclear whether inflammatory markers C-reactive protein (CRP) and interleukin-6 (IL-6) associate with PCa risk in older men. Using Cox regression, we assessed the relationship between baseline concentrations of CRP and IL-6 and the subsequent PCa risk in the Cardiovascular Health Study, a population-based cohort study of mostly European American men of ages >64 years (n = 2,234; mean follow-up = 8.7 years; 215 incident PCa cases). We also tested associations between CRP and IL-6 tagSNPs and PCa risk, focusing on SNPs that are known to associate with circulating CRP and/or IL-6. Neither CRP nor IL-6 blood concentrations was associated with PCa risk. The C allele of IL-6 SNP rs1800795 (-174), a known functional variant, was associated with increased risk in a dominant model (HR = 1.44; 95% CI = 1.03-2.01; p = 0.03), but was not statistically significant after accounting for multiple tests (permutation p = 0.21). Our results suggest that circulating CRP and IL-6 do not influence PCa risk. SNPs at the CRP locus are not associated with PCa risk in this cohort, while the association between rs1800795 and PCa risk warrants further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.